Printer Friendly

More Uses for Tenofovir?

The recently approved antiretroviral tenofovir may be particularly important, because it appears to have fewer side effects than other antiretrovirals, and also less problem with resistance. It might be ideal for prevention of maternal transmission of HIV -- and possibly could be reformulated as an effective microbicide, allowing women to protect themselves from HIV infection without relying on men. But because tenofovir was first tested in treatment of advanced fflV disease, it seems to have been largely kept on the shelf for other uses, pending more data. Trials in first-line therapy are ongoing now.

We suspect this drug deserves more attention now, even before completion of the current trials (they will not answer all the questions anyway). It could be especially important as a starting point for developing low-side-effect treatments for patients who otherwise have poor options because of severe toxicities with other drugs. In the real world, we cannot answer every question with formal trials, so we should collect experience systematically to get the best information possible. We need to investigate: if reasonably effective antiretroviral regimens with less serious side effects are possible using the drugs now approved; if major resistance to tenofovir does develop, does the virus pay a price in ways that reduces its ability to cause disease; and even whether it might make sense to use this drug alone for certain patients -- not as a good option, but possibly a better option than any other available to them.

We should also look into why this treatment was so much more effective as an antiviral in some animal trials with viruses related to HIV, than in human studies. Some of the animal tests found huge viral load reductions when the drug was used alone, compared to only about a 0.6 log reduction in patients. Could this difference have been due to the fact that the animal studies injected the active substance (PMPA), while humans use an oral prodrug (tenofovir) designed to be converted to PMPA by the body? Pharmaceutical companies have usually stayed away from any HIV drug that would have to be injected frequently. But if an injected drug had anywhere near the antiretroviral potency of PMPA in the animal trials, many people would very much want to use it. (A larger dose of the oral tenofovir is apparently not more effective, so the difference would not be just from the dose.)
COPYRIGHT 2002 John S. James
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:AIDS Treatment News
Geographic Code:1USA
Date:Jan 25, 2002
Words:396
Previous Article:Drug interactions need more attention.
Next Article:New kinds of treatment.
Topics:


Related Articles
Retroviruses Conference: Johns Hopkins Report.
HIV Resistance Meeting Web Reports.
Tenofovir: FDA Hearing October 3, Public Comment Deadlines September 26.
Tenofovir approved: Broad indication.
Treatment news from recent conferences: Finding web reports.
HIV medicine after Barcelona conference: interview with Howard Grossman, M.D.
Prevention: New approach will test tenofovir for persons at high risk.
After N-9, what next? Several potential microbicides are poised to be tested for effectiveness in humans.
Failure of combination abacavir + tenofovir + lamivudine (3TC).
Antiretroviral pipeline: new-drug reports from retroviruses conference.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters